Rena Conti

Dean’s Research Scholar Associate Professor, Markets, Public Policy, and Law Associate Research Director, Institute for Health System Innovation and Policy
  • Phone 617-353-1156
  • Office 514B
  • BOSTON UNIVERSITY
    Questrom School of Business
    Rafik B. Hariri Building
    595 Commonwealth Avenue
    Boston, MA 02215

  • Download CV
    Publications
  • Chua, K., Lee, J., Conti, R. (2021). "Potential Change in Insulin Out-of-Pocket Spending Under Cost-Sharing Caps Among Pediatric Patients With Type 1 Diabetes.", JAMA Pediatr, 175 (1), 90-92
  • Padula, W., Parasrampuria, S., Socal, M., Conti, R., Anderson, G. (2020). "Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US".", Pharmacoeconomics, 38 (12), 1375-1376
  • Mattingly, T., Seo, D., Ostrovsky, A., Vanness, D., Conti, R. (2020). "60 Years after Kefauver: Household income required to buy prescription drugs in the United States and abroad.", Res Social Adm Pharm
  • Chua, K., Conti, R. (2020). "Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.", JAMA Intern Med, 180 (10), 1273-1274
  • Padula, W., Parasrampuria, S., Socal, M., Conti, R., Anderson, G. (2020). "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US.", Pharmacoeconomics, 38 (10), 1115-1121
  • Chua, K., Conti, R. (2020). "Trends In Orphan Drug Spending And Out-Of-Pocket Spending Among US Children, 2013-18.", Health Aff (Millwood), 39 (10), 1806-1811
  • Chua, K., Lee, J., Conti, R. (2020). "Out-of-Pocket Spending for Insulin, Diabetes-Related Supplies, and Other Health Care Services Among Privately Insured US Patients With Type 1 Diabetes.", JAMA Intern Med, 180 (7), 1012-1014
  • Kimmel, L., Conti, R., Volerman, A., Chua, K. (2020). "Pediatric Orphan Drug Indications: 2010-2018.", Pediatrics, 145 (4)
  • Nikpay, S., Buntin, M., Conti, R. (2020). "Relationship between initiation of 340B participation and hospital safety-net engagement.", Health Serv Res, 55 (2), 157-169
  • Conti, R., Dusetzina, S., Sachs, R. (2020). "How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts.", Health Aff (Millwood), 39 (3), 445-452
  • Chua, K., Brummett, C., Conti, R., Bohnert, A. (2020). "Association of Opioid Prescribing Patterns With Prescription Opioid Overdose in Adolescents and Young Adults.", JAMA Pediatr, 174 (2), 141-148
  • Chua, K., Schwartz, A., Volerman, A., Conti, R., Huang, E. (2020). "Differences in the Receipt of Low-Value Services Between Publicly and Privately Insured Children.", Pediatrics, 145 (2)
  • Fox, E., Conti, R. (2020). "Pharmacy Forecast 2020: Pharmaceutical Supply Chain", AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 77 (2), 101-103
  • Vermeulen, L., Swarthout, M., Alexander, G., Ginsburg, D., Pritchett, K., White, S., Tryon, J., Emmerich, C., Nesbit, T., Greene, W., Fox, E., Conti, R., Scott, B., Sheehy, F., Melby, M., Lantzy, M., Hoffman, J., Knoer, S., Zellmer, W. (2020). "ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems.", Am J Health Syst Pharm, 77 (2), 84-112
  • Conti, R., David, F. (2020). "Public research funding and pharmaceutical prices: do Americans pay twice for drugs?", F1000Res, 9 707-
  • Woo, J., Anderson, B., Gruenstein, D., Conti, R., Chua, K. (2019). "Minimum Travel Distance Among Publicly Insured Infants with Severe Congenital Heart Disease: Potential Impact of In-state Restrictions.", Pediatr Cardiol, 40 (8), 1599-1608
  • Chen, A., Hu, X., Conti, R., Jena, A., Goldman, D. (2019). "Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.", Value Health, 22 (12), 1387-1395
  • Conti, R., Berndt, E., Shivdasani, Y., Kaygisiz, N. (2019). "The Geography of Prescription Pharmaceuticals Supplied to the U.S.: Levels, Trends and Implications",
  • Conti, R. (2019). "Financial Toxicity of Prescription Drugs.", Ann Intern Med, 171 (9), 665-666
  • Conti, R., Berndt, E., Adajar, P. (2019). "The Surprising Hybrid Pedigree of Measures of Diversity and Economic Concentration",
  • Conti, R., Nikpay, S., Buntin, M. (2019). "Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016", JAMA Network Open, 2 (10), e1914141-e1914141
  • Conti, R. (2019). "3 Things You Need to Know About Prescription Drug Affordability", Institute for Health System Innovation & Policy
  • Conti, R. (2019). "The Orphan Drug Act: IHSIP Expertise in Policy Action",
  • Conti, R., Berndt, E. (2019). "Four Facts Concerning Competition in US Generic Prescription Drug Markets", International Journal of the Economics of Business 1-22
  • Conti, R., Berndt, E. (2019). "Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets",
  • Conti, R., Kleutghen, P. (2019). "Is ‘Competitive Licensing’ Proposed In HR 1046 Practical For Lowering Drug Prices?", Health Affairs
  • Conti, R., Chua, K. (2019). "Orphan Drugs For Opioid Use Disorder: An Abuse Of The Orphan Drug Act", Health Affairs
  • Royce, T., Kircher, S., Conti, R. (2019). "Pharmacy Benefit Manager Reform", JAMA, 322 (4), 299-299
  • Conti, R., David, F. (2019). "Rebalancing High Prescription Drug Prices With Innovation Incentives", Health Affairs
  • Chua, K., Brummett, C., Conti, R., Haffajee, R., Prosser, L., Bohnert, A. (2019). "Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids", JAMA Network Open, 2 (5), e193673-e193673
  • Chua, K., Conti, R. (2019). "Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014", Journal of General Internal Medicine, 34 (3), 338-340
  • GaBI Journal Editor, . (2018). "US generic prescription drug markets 2004–2016", Generics and Biosimilars Initiative Journal, 7 (4), 164-164
  • Parsons, S., Castellino, S., Rodday, A., Keller, F., Kelly, K., Conti, R., Lerner, D., Henderson, T. (2018). "Productivity Loss Among Parent Caregivers Is Associated with Poor Health-Related Quality of Life (HRQL) at the Intial Diagnosis of Pediatric Advanced Stage Hodgkin Lymphoma (HL)", Blood, 132 (Supplement 1), 975-975
  • Conti, R., Nikpay, S., Buntin, M. (2018). "Diversity of Participants in the 340B Drug Pricing Program for US Hospitals", Journal of the American Medical Association Internal Medicine, 178 (8), 1124-1127
  • Conti, R., Nguyen, K., Rosenthal, M. (2018). "Generic Prescription Drug Price Increases: Which Products Will Be Affected by Proposed Anti-Gouging Legislation", Journal of Pharmaceutical Policy and Practice, 11 (1), 29-29
  • Conti, R., Chua, K. (2018). "Out-of-Pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014", Journal of General Internal Medicine, 178 (4), 133-140
  • (2018). "AMCP Partnership Forum: Driving Value and Outcomes in Oncology.", J Manag Care Spec Pharm, 24 (6), 572-578
  • Parsons, S., Lerner, D., Rodday, A., Curtis, R., Kelly, K., Conti, R., Castellino, S., Henderson, T. (2018). "Parental work limitations at diagnosis of advanced stage pediatric Hodgkin lymphoma—Results of caregiver work limitations questionnaire (CG WLQ).", Journal of Clinical Oncology, 36 (15_suppl), e18927-e18927
  • Berndt, E., Conti, R., Murphy, S. (2018). "The generic drug user fee amendments: an economic perspective", Journal of Law and the Biosciences, 5 (1), 103-141
  • Aggarwal, M., Devries, S., Freeman, A., Ostfeld, R., Gaggin, H., Taub, P., Rzeszut, A., Allen, K., Conti, R. (2018). "The Deficit of Nutrition Education of Physicians.", Am J Med, 131 (4), 339-345
  • Conti, R., Berndt, E. (2018). Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001–2007. In David, Cutler. (Eds.), "Measuring and Modeling Health Care Costs Advances in CRIW Conference Proceedings", University of Chicago Press
  • Conti, R., Chua, K., Shrime, M. (2017). "Effect of FDA Investigation on Opioid Prescribing to Children after Tonsillectomy/Adenoidectomy", Pediatrics, 140 (6), 6-6
  • Conti, R. (2017). "Making Medicines Affordable: A National Imperative — A Review", Health Affairs
  • Conti, R., Nikpay, S., Buntin, M. (2017). "The 340B Program: Mandatory Reporting, Alternative Eligibility Criteria Should Be Top Priorities for Congress", Health Affairs
  • Dusetzina, S., Conti, R., Yu, N., Bach, P. (2017). "Association of Prescription Drug Price Rebates in Medicare Part D with Patient Out-of-Pocket and Federal Spending", Journal of the American Medical Association Internal Medicine, 177 (8), 1185-1188
  • Conti, R. (2017). "Biosimilars: Reimbursement Issues in Your Oncology Practice", Journal of Oncology Practice, 13 (9), 12-14
  • Conti, R., DeSouza, J. (2017). "Mitigating Financial Toxicity among US Patients with Cancer", Journal of the American Medical Association Oncology, 3 (6), 765-766
  • Conti, R. (2017). "Biosimilars: Reimbursement Issues in Your Oncology Practice.", Journal of oncology practice, 13 (9_suppl), 12s-14s
  • Conti, R., Berndt, E. (2017). "The Generic Drug User Fee Amendments: An Economic Perspective",
  • Conti, R., Murphy, S., Berndt, E. (2017). "The Landscape of US Generic Prescription Drug Markets, 2004–2016", The National Bureau of Economic Research
  • Conti, R., Chua, K. (2017). "Out-of-Pocket Spending among Commercially Insured Patients for Epinephrine Autoinjectors between 2007 and 2014", Journal of the American Medical Association Internal Medicine, 176 (2), 736-739
  • Chua, K., Conti, R. (2017). "Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014.", JAMA Intern Med, 177 (5), 736-739
  • Conti, R., Jones, D. (2017). "Policy Diffusion across Disparate Disciplines: Private- and Public-Sector Dynamics Affecting State-Level Adoption of the ACA", Journal of Health Politics, Policy and Law, 42 (2), 377-385
  • Chua, K., Conti, R., Freed, G. (2017). "Appropriately Framing Child Health Care Spending: A Prerequisite for Value Improvement",
  • Conti, R., padula, w. (2017). Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the U.S. and the E.U.. In Richard, Hehlmann. (Eds.), "Chronic Myeloid Leukemia: What Every Clinical Practitioner Needs to Know in 2017", ASCO
  • Dragoni, F., Conti, R., Cazzaniga, S., Colucci, R., Pisaneschi, L., Naldi, L., Moretti, S. (2017). "No Association between Vitiligo and Obesity: A Case-Control Study.", Med Princ Pract, 26 (5), 421-426
  • Henderson, T., Castellino, S., Keller, F., Kelly, K., Curtis, R., Conti, R., Parsons, S. (2016). "Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III Clinical Trial for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Children and Adolescents", Blood, 128 (22), 3583-3583
  • Darlington, W., Watson, S., Henderson, T., Cunningham, J., Conti, R. (2016). "The Affordable Care Act Improves Healthcare Access and Utilization Among Young Adults with Sickle Cell Disease", BLOOD, 128 (22)
  • Chua, K., Schwartz, A., Volerman, A., Conti, R., Huang, E. (2016). "Use of Low-Value Pediatric Services Among the Commercially Insured", PEDIATRICS, 138 (6), e20161809-e20161809
  • Conti, R., Gee, R., Sharfstein, J. (2016). "Pharmaceuticals and Public Health.", JAMA, 316 (20), 2083-2084
  • Pitts, P., Louet, H., Moride, Y., Conti, R. (2016). "21st century pharmacovigilance: efforts, roles, and responsibilities.", Lancet Oncol, 17 (11), e486-e492
  • Castellino, S., Henderson, T., Keller, F., Kelly, K., Curtis, R., Conti, R., Parsons, S. (2016). "APPROACH AND FEASIBILITY OF PATIENT-REPORTED OUTCOMES IN A PHASE III CLINICAL TRIAL FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN CHILDREN AND ADOLESCENTS", HAEMATOLOGICA, 101 37-37
  • Conti, R. (2016). "The Advantages of Awarding the Federal Government Negotiating Power Over the Prices of Prescription Drugs", Journal of Policy Analysis and Management, 35 (4), 964-970
  • Conti, R. (2016). "Response to Joyce and Sood", Journal of Policy Analysis and Management, 35 (4), 972-974
  • Padula, W., Larson, R., Dusetzina, S., Apperley, J., Hehlmann, R., Baccarani, M., Eigendorff, E., Guilhot, J., Guilhot, F., Hehlmann, R., Mahon, F., Martinelli, G., Mayer, J., Müller, M., Niederwieser, D., Saussele, S., Schiffer, C., Silver, R., Simonsson, B., Conti, R. (2016). "Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.", J Natl Cancer Inst, 108 (7)
  • Polite, B., Ward, J., Cox, J., Morton, R., Hennessy, J., Page, R., Conti, R. (2016). "A Pathway Through the Bundle Jungle.", J Oncol Pract, 12 (6), 504-509
  • Weiner, A., Conti, R., Eggener, S. (2016). "National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions.", J Urol, 195 (5), 1383-1389
  • Clark, B., Hou, J., Huang, E., Conti, R., Chou, C. (2016). "Medication Adherence among Hiv/Aids Patients Receiving 340b-Purchased Antiretroviral Medications", Value in Health, 19 (3), A8-A8
  • Bach, P., Conti, R., Muller, R., Schnorr, G., Saltz, L. (2016). "Overspending driven by oversized single dose vials of cancer drugs.", BMJ, 352 i788-
  • Conti, R., Rosenthal, M. (2016). "Pharmaceutical Policy Reform--Balancing Affordability with Incentives for Innovation.", N Engl J Med, 374 (8), 703-706
  • Dusetzina, S., Ellis, S., Freedman, R., Conti, R., Winn, A., Chambers, J., Alexander, G., Huskamp, H., Keating, N. (2015). "How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab.", J Oncol Pract, 11 (4), 313-318
  • Padula, W., Larson, R., Conti, R., Dusetzina, S. (2015). "Comparing tyrosine kinase inhibitor treatment strategies for newly diagnosed chronic myeloid leukemia in chronic phase when imatinib loses patent exclusivity in the u.s.: a cost-effectiveness analysis", Value in Health, 18 (3), A205-A205
  • Polite, B., Ward, J., Cox, J., Morton, R., Hennessy, J., Page, R., Conti, R. (2015). "Reply to M. Thompson et Al.", J Oncol Pract, 11 (3), 263-264
  • Conti, R., Padula, W., Larson, R. (2015). "Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.", Ann Hematol, 94 Suppl 2 S249-S257
  • Gibbons, R., Coca Perraillon, M., Hur, K., Conti, R., Valuck, R., Brent, D. (2015). "Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents.", Pharmacoepidemiol Drug Saf, 24 (2), 208-214
  • Conti, R. (2015). "Expanding the Scope of the National Practice Oncology Benchmark Would Be a Critical Source for Understanding Outpatient Oncology Practice Costs and Profits in a Time of Change.", J Oncol Pract, 11 (1), e95-e97
  • Polite, B., Conti, R., Ward, J. (2015). "Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist.", Am Soc Clin Oncol Educ Book e75-e80
  • Howard, D., Bach, P., Berndt, E., Conti, R. (2015). "Pricing in the Market for Anticancer Drugs.", J Econ Perspect, 29 (1), 139-162
  • Larson, R., Conti, R., Padula, W., Apperley, J., Baccarani, M., Eigendorff, E., Guilhot, F., Guilhot, J., Mahon, F., Martinelli, G., Mayer, J., Mueller, M., Niederwieser, D., Saussele, S., Schiffer, C., Silver, R., Simonsson, B., Hehlmann, R. (2014). "What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?", Blood, 124 (21), 738-738
  • Polite, B., Ward, J., Cox, J., Morton, R., Hennessy, J., Page, R., Conti, R. (2014). "Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.", J Oncol Pract, 10 (6), 357-362
  • Conti, R., Bach, P. (2014). "Improving outpatient oncology practice: several steps into a long journey.", J Oncol Pract, 10 (6), 355-356
  • Clark, B., Hou, J., Chou, C., Huang, E., Conti, R. (2014). "The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.", Health Aff (Millwood), 33 (11), 2012-2017
  • Padula, W., Conti, R., Larson, R. (2014). "What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?", Value Health, 17 (7), A636-
  • Dusetzina, S., Winn, A., Chambers, J., Ellis, S., Conti, R., Freedman, R., Alexander, G., Keating, N., Huskamp, H. (2014). "Payer-Level Differences in the Response to Regulatory Actions Regarding Withdrawal of Breast Cancer as an Indication for Bevacizumab", JOURNAL OF WOMENS HEALTH, 23 (10), 857-857
  • Conti, R., Fein, A., Bhatta, S. (2014). "National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011.", Health Aff (Millwood), 33 (10), 1721-1727
  • Conti, R., Bach, P. (2014). "The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.", Health Aff (Millwood), 33 (10), 1786-1792
  • Howard, D., Conti, R. (2014). "Are new drugs more expensive than old ones? Trends in the benefit-adjusted launch prices of anticancer drugs, 1995-2013.", Journal of Clinical Oncology, 32 (15_suppl), 6525-6525
  • Goldberg, P., Conti, R. (2014). "Problems with public reporting of cancer quality outcomes data.", J Oncol Pract, 10 (3), 215-218
  • Conti, R. (2013). "Drug discount program--reply.", JAMA, 310 (15), 1627-
  • Conti, R., Dusetzina, S., Herbert, A., Berndt, E., Huskamp, H., Keating, N. (2013). "The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer.", Med Care, 51 (7), 622-627
  • Conti, R., Bach, P. (2013). "Cost consequences of the 340B drug discount program.", JAMA, 309 (19), 1995-1996
  • Kornfield, R., Watson, S., Higashi, A., Conti, R., Dusetzina, S., Garfield, C., Dorsey, E., Huskamp, H., Alexander, G. (2013). "Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.", Psychiatr Serv, 64 (4), 339-346
  • Conti, R., Bernstein, A., Villaflor, V., Schilsky, R., Rosenthal, M., Bach, P. (2013). "Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.", J Clin Oncol, 31 (9), 1134-1139
  • Bhatta, S., Fein, A., Conti, R. (2013). "TRENDS IN SPENDING ON ORAL CHEMOTHERAPEUTIC AGENTS 2006-2012", CLINICAL PHARMACOLOGY & THERAPEUTICS, 93 S12-S12
  • Dusetzina, S., Busch, A., Conti, R., Donohue, J., Alexander, G., Huskamp, H. (2012). "Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory.", Pharmacoepidemiol Drug Saf, 21 (12), 1251-1260
  • Dusetzina, S., Higashi, A., Dorsey, E., Conti, R., Huskamp, H., Zhu, S., Garfield, C., Alexander, G. (2012). "Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.", Med Care, 50 (6), 466-478
  • Conti, R., Rosenthal, M., Polite, B., Bach, P., Shih, Y. (2012). "Infused chemotherapy use in the elderly after patent expiration.", Am J Manag Care, 18 (5), e173-e178
  • Conti, R., Rosenthal, M., Polite, B., Bach, P., Shih, Y. (2012). "Infused chemotherapy use in the elderly after patent expiration.", J Oncol Pract, 8 (3 Suppl), e18s-e23s
  • Philipson, T., Eber, M., Lakdawalla, D., Corral, M., Conti, R., Goldman, D. (2012). "An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer.", Health Aff (Millwood), 31 (4), 667-675
  • Garfield, C., Dorsey, E., Zhu, S., Huskamp, H., Conti, R., Dusetzina, S., Higashi, A., Perrin, J., Kornfield, R., Alexander, G. (2012). "Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010.", Acad Pediatr, 12 (2), 110-116
  • Pillarella, J., Higashi, A., Alexander, G., Conti, R. (2012). "Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009.", Psychiatr Serv, 63 (1), 83-86
  • Conti, R., Bernstein, A., Meltzer, D. (2012). "How do initial signals of quality influence the diffusion of new medical products? The case of new cancer drug treatments.", Adv Health Econ Health Serv Res, 23 123-148
  • Dusetzina, S., Alexander, G., Conti, R., Dorsey, E., Higashi, A., Zhu, S., Garfield, C., Huskamp, H. (2011). "Predictors of High Metabolic Risk Antipsychotic Use", PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 20 S264-S264
  • Garfield, C., Dorsey, E., Zhu, S., Higashi, A., Huskamp, H., Conti, R., Dusetzina, S., Alexander, G. (2011). "US Trends in the Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder, 2000-2010", PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 20 S197-S197
  • Conti, R. (2011). "Overuse of Antidepressants in a Nationally Representative Adult Patient Population in 2005", Psychiatric Services, 62 (7), 720-720
  • Conti, R., Busch, A., Cutler, D. (2011). "Overuse of antidepressants in a nationally representative adult patient population in 2005.", Psychiatr Serv, 62 (7), 720-726
  • Alexander, G., Garfield, C., Dorsey, R., Zhu, S., Higashi, A., Huskamp, H., Conti, R., Dusetzina, S. (2011). "US TRENDS IN THE DIAGNOSIS AND TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER, 2000-2010", JOURNAL OF GENERAL INTERNAL MEDICINE, 26 S253-S253
  • Qato, D., Lindau, S., Conti, R., Schumm, L., Alexander, G. (2010). "Racial and ethnic disparities in cardiovascular medication use among older adults in the United States.", Pharmacoepidemiol Drug Saf, 19 (8), 834-842
  • Conti, R., Veenstra, D., Armstrong, K., Lesko, L., Grosse, S. (2010). "Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.", Med Decis Making, 30 (3), 328-340
  • Conti, R. (2010). "Advances in economics to further inform investments in vaccine development", Human Vaccines, 6 (4), 286-291
  • Conti, R. (2010). "Advances in economics to further inform investments in vaccine development.", Hum Vaccin, 6 (4), 289-291
  • Dorsey, R., Rabbani, A., Gallagher, S., Conti, R., Alexander, G. (2010). "IMPACT OF FDA BLACK BOX ADVISORY ON ANTIPSYCHOTIC MEDICATION USE", JOURNAL OF INVESTIGATIVE MEDICINE, 58 (4), 675-675
  • Dorsey, E., Rabbani, A., Gallagher, S., Conti, R., Alexander, G. (2010). "Impact of FDA black box advisory on antipsychotic medication use.", Arch Intern Med, 170 (1), 96-103
  • Meltzer, D., Basu, A., Conti, R. (2010). "The economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research.", Pharmacoeconomics, 28 (10), 843-853
  • Conti, R., Banks, J., Cornaglia, F. (2009). "LABOUR MARKET PARTICIPATION AND DEPRESSIVE SYMPTOMS AT OLDER AGES IN THE US AND UK", GERONTOLOGIST, 49 19-19
  • Qato, D., Lindau, S., Conti, R., Alexander, G. (2009). "PIH51 Racial/Ethnic Disparities in Prescription Drug Use Among Older Adults in the United States", Value in Health, 12 (3), A171-A171
  • Conti, R. (2009). "Value of research analysis: an application to drug development.", Clin Adv Hematol Oncol, 7 (5), 298-300
  • Qato, D., Alexander, G., Conti, R., Johnson, M., Schumm, P., Lindau, S. (2008). "Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States.", JAMA, 300 (24), 2867-2878
  • Conti, R., Meltzer, D., Ratain, M. (2008). "Nonprofit biomedical companies.", Clin Pharmacol Ther, 84 (2), 194-197
  • Conti, R. (2008). "The societal benefit of nonprofit biotechnology companies.", Clin Adv Hematol Oncol, 6 (5), 366-386
  • Rosenthal, M., Landrum, M., Meara, E., Huskamp, H., Conti, R., Keating, N. (2007). "Using performance data to identify preferred hospitals.", Health Serv Res, 42 (6 Pt 1), 2109-2119
  • Chien, A., Conti, R., Pollack, H. (2007). "A pediatric-focused review of the performance incentive literature.", Curr Opin Pediatr, 19 (6), 719-725
  • Frank, R., Conti, R., Goldman, H. (2005). "Mental Health Policy and Psychotropic Drugs", The Milbank Quarterly, 83 (2), 271-298
  • Epstein, A., Ayanian, J., Keogh, J., Noonan, S., Armistead, N., Cleary, P., Weissman, J., David-Kasdan, J., Carlson, D., Fuller, J., Marsh, D., Conti, R. (2000). "Racial disparities in access to renal transplantation--clinically appropriate or due to underuse or overuse?", N Engl J Med, 343 (21), 1537-1544